PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVaborbactam
Vaborbactam
Vabomere, Vaborem (vaborbactam) is a small molecule pharmaceutical. Vaborbactam was first approved as Vabomere on 2017-08-29. It is used to treat bacterial infections in the USA. It has been approved in Europe to treat bacteremia, bacterial infections, pneumonia, respiratory tract infections, and urinary tract infections amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
vabomereNew Drug Application2025-03-25
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
MEROPENEM / VABORBACTAM, VABOMERE, REMPEX
2027-08-29GAIN
2022-08-29NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Meropenem / Vaborbactam, Vabomere, Rempex
113762372039-04-06U-3421
86801362031-08-29DS, DP
96940252031-08-08U-2120
101728742031-08-08DP
101830342031-08-08U-2490
105616752031-08-08U-2490
110072062031-08-08U-3128
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DH: Carbapenems
— J01DH52: Meropenem and vaborbactam
HCPCS
Code
Description
J2186
Injection, meropenem and vaborbactam, 10mg/10mg (20mg)
Clinical
Clinical Trials
16 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gram-negative bacterial infectionsD016905———1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVaborbactam
INNvaborbactam
Description
Vaborbactam (INN) is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them. When combined with an appropriate antibiotic it can be used for the treatment of gram-negative bacterial infections.
Classification
Small molecule
Drug classbeta-lactamase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C(O)C[C@@H]1CC[C@H](NC(=O)Cc2cccs2)B(O)O1
Identifiers
PDB—
CAS-ID1360457-46-0
RxCUI—
ChEMBL IDCHEMBL3317857
ChEBI ID—
PubChem CID56649692
DrugBankDB12107
UNII ID1C75676F8V (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,755 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
87 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use